Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders in precise figures. The company mentions a portfolio of projects across various phases: 41 projects in Phase-II and 2 in Phase-III, with ongoing churning as about 30 to 40 molecules exit and new ones enter annually. They have visibility of about six months on project progress, indicating limited forecasting ability for order pipelines. The company is filing 10 ANDAs over the next 4-5 years targeting products going off-patent in 2-3 years, expected to generate net profits of USD 2-3 million

Any current/future new fundraising through debt or equity?

There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript. The company appears to be utilizing spare capital by investing in mutual funds rather than raising new funds. Capital expenditure plans include a Rs.120 crore investment for a new block at Pashamylaram, implying internal funding rather than new external fundraising. The company focuses on leveraging existing infrastructure to manage costs, indicating cautious capital management without reliance on fresh capital raising. No explicit plans or indications of new debt or equity issua

Future growth expectations in sales/revenue/volumes?

Suven Life Sciences expects a 10% to 15% growth in topline (revenue) and bottom-line (profits) going forward. The CRAMS business growth is linked more to the success of molecules moving through clinical phases than just the number of projects, which typically churns with 30-40 molecules leaving and joining annually. Specialty Chemicals is expected to have minimal growth, around ±5% annually, as it is a mature product line. The launch quantities for commercial molecules are anticipated to exceed previous guidance (around Rs. 60-70 crore annually). Continued investment in NCE (New Chemical Entit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a growth rate of around 10% to 15% in topline and bottom-line (PAT), maintaining similar margins. For the current fiscal year, revenue guidance is Rs. 60-70 crore from commercialized molecules, with potential to exceed this. Operational profits may grow modestly as R&D expenses increase marginally, reflecting ongoing clinical trials and development costs. Specialty Chemicals segment is expected to remain stable with about ±5% growth, as it comprises mature products. The launch of new NCE (New Chemical Entity) pipeline molecules each year adds long-term value but wit

IN US

Sale is live|00:00:00left today

Suven Life Sciences LtdQ2 FY17Healthcare Services

Suven Life Sciences Ltd Q2 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268Market Cap: ₹5.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Suven Life Sciences expects a 10% to 15% growth in topline (revenue) and bottom-line (profits) going forward.
→The CRAMS business growth is linked more to the success of molecules moving through clinical phases than just the number of projects, which typically churns with 30-40 molecules leaving and joining annually.
→Specialty Chemicals is expected to have minimal growth, around ±5% annually, as it is a mature product line.
→The launch quantities for commercial molecules are anticipated to exceed previous guidance (around Rs. 60-70 crore annually).
→Continued investment in NCE (New Chemical Entities) is expected to mature over time, adding value.
→No visibility beyond six months on clinical timelines and commercial ramp-ups, leading to cautious yet positive growth outlook.
→Infrastructure expansion supports leveraging existing assets without major capital increases, indicating scalability with current resources.

Margin guidance

Category 3

→The company expects a growth rate of around 10% to 15% in topline and bottom-line (PAT), maintaining similar margins.
→For the current fiscal year, revenue guidance is Rs. 60-70 crore from commercialized molecules, with potential to exceed this.
→Operational profits may grow modestly as R&D expenses increase marginally, reflecting ongoing clinical trials and development costs.
→Specialty Chemicals segment is expected to remain stable with about ±5% growth, as it comprises mature products.
→The launch of new NCE (New Chemical Entity) pipeline molecules each year adds long-term value but with inherent risk; blockbuster success is not promised but potential exists.
→R&D expenses are expected to have a marginal increase, mainly for ongoing trials like SUVN-502 and new initiatives like 911 trial.
→Tax expenses will move to normal levels (~30-34%) due to reduced weighted deductions, impacting net profit accordingly.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company appears to be utilizing spare capital by investing in mutual funds rather than raising new funds.
→Capital expenditure plans include a Rs.120 crore investment for a new block at Pashamylaram, implying internal funding rather than new external fundraising.
→The company focuses on leveraging existing infrastructure to manage costs, indicating cautious capital management without reliance on fresh capital raising.
→No explicit plans or indications of new debt or equity issuance are discussed in this call.

Order book

→The transcript does not provide explicit details on the current or expected order book or pending orders in precise figures.
→The company mentions a portfolio of projects across various phases: 41 projects in Phase-II and 2 in Phase-III, with ongoing churning as about 30 to 40 molecules exit and new ones enter annually.
→They have visibility of about six months on project progress, indicating limited forecasting ability for order pipelines.
→The company is filing 10 ANDAs over the next 4-5 years targeting products going off-patent in 2-3 years, expected to generate net profits of USD 2-3 million per product.
→There is commercial supply visible (approx Rs. 25 crore in the quarter) and guidance for Rs. 60-70 crore revenue in CRAMS business this year, possibly exceeding that.
→Overall, the orderbook appears dynamic but growing at a steady rate of approximately 10-15% annually.

Capex plans

Yes

- Rs. 120 crore CAPEX planned for creation of a new specialty chemicals block at Pashamylaram, meeting OEL4 requirements (Page 12). - Maintenance CAPEX expected to be Rs. 20-25 crore, roughly 10-15% of regular requirements (Page 12). - Rs. 100 crore investment towards expansion for increased API production capacity from 7.5 tonnes to 75 tonnes per month through phased environmental clearance (Pages 10). - Expansion permissions already obtained for maximum capacity based on plot limits to avoid future licensing needs (Page 10). - Regular CAPEX additions ongoing, in addition to previous Vizag Specialty Chemicals facility capitalization (Page 8). - The R&D infrastructure created is leveraged for new generic ANDA filings; any incremental costs are mostly recurring expenditures (Page 16). Overall, significant capital investment is underway primarily for specialty chemicals facility expansion and infrastructure to support growth in NCE and generic pipelines.

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

1Suven Life Sciences Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Suven Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio